CST, 98611T, CRACC/SLAMF7/CD319 (E5C4M) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying CRACC/SLAMF7. Validated for Western Blotting,IHC Leica Bond,Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, CRACC/SLAMF7/CD319 (E5C4M) Rabbit Monoclonal Antibody (CST #98611) is ready to ship. Product Usage Information Western Blotting: 1:1000 IHC Leica Bond: 1:400 Immunohistochemistry (Paraffin): 1:150 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 66110 . Protocol Available protocols: Western Blotting, IHC Leica Bond, Immunohistochemistry (Paraffin) Specificity / Sensitivity CRACC/SLAMF7/CD319 (E5C4M) Rabbit Monoclonal Antibody recognizes endogenous levels of total CRACC/SLAMF7/CD319 protein. This antibody may cross-react with several isoforms of CRACC/SLAMF7/CD319 and with varying levels of glycosylation. Non-specific staining was observed in prostate epithelium. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human CRACC/SLAMF7/CD319 protein. Background CRACC/SLAMF7/CD319 (also known as CS1) is a member of the signaling lymphocytic activation molecule (SLAM) family. It is a single-pass type l transmembrane glycoprotein expressed on NK cells, subsets of mature dendritic cells, activated B and T lymphocytes, but not in promyelocytic B or T cell lines. Expression of this protein has been detected in the spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung, and trachea (1-5). Homophilic interactions of CRACC/SLAMF7/CD319 modulate the activity and differentiation of immune cells. CRACC/SLAMF7/CD319 may function as an inhibitory or activating receptor in immune cells depending on cellular context and availability of adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2 (4-8). In the presence of SH2D1B/EAT-2, CRACC/SLAMF7/CD319 activates NK cells and B cells (4-6). T cells lack SH2D1B/EAT-2 expression, and therefore CRACC/SLAMF7/CD319 acts as an inhibitory receptor (7). In LPS-activated monocytes, CRACC/SLAMF7/CD319 negatively regulates production of proinflammatory cytokines (8). CRACC/SLAMF7/CD319 is upregulated in multiple myeloma and is implicated in the uncontrolled proliferation of these cells, and thus has become the target for therapeutic intervention (9,10). Seven isoforms of CRACC/SLAMF7/CD319 produced by alternative splicing have been identified. Alternate Names 19A; 19A24 protein; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CD2-like receptor-activating cytotoxic cells; CD319; CRACC; CS1; Membrane protein FOAP-12; Novel Ly9; novel LY9 (lymphocyte antigen 9) like protein; Protein 19A; SLAF7; SLAM family member 7; SLAMF7 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 25-80 Source/Isotype: Rabbit IgG